9.36
-0.30 (-3.11%)
| Previous Close | 9.66 |
| Open | 10.05 |
| Volume | 7,448,509 |
| Avg. Volume (3M) | 4,644,987 |
| Market Cap | 1,958,579,968 |
| Price / Earnings (Forward) | 53.48 |
| Price / Sales | 3.88 |
| Price / Book | 56.59 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -10.62% |
| Operating Margin (TTM) | 14.59% |
| Diluted EPS (TTM) | -0.260 |
| Quarterly Revenue Growth (YOY) | 56.90% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -25.85 M |
| Levered Free Cash Flow (TTM) | 42.90 M |
| Return on Assets (TTM) | 4.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | BioCryst Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.20% |
| % Held by Institutions | 85.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 220.51%) | Buy |
| Median | 17.00 (81.62%) | |
| Low | 11.00 (Barclays, 17.52%) | Hold |
| Average | 17.43 (86.22%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 9.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 30 Jun 2025 | 13.00 (38.89%) | Buy | 9.36 |
| 06 May 2025 | 13.00 (38.89%) | Buy | 10.27 | |
| Wedbush | 30 Jun 2025 | 18.00 (92.31%) | Buy | 9.36 |
| Needham | 27 Jun 2025 | 17.00 (81.62%) | Buy | 9.36 |
| 25 Jun 2025 | 17.00 (81.62%) | Buy | 9.74 | |
| Barclays | 07 May 2025 | 11.00 (17.52%) | Hold | 10.08 |
| HC Wainwright & Co. | 06 May 2025 | 30.00 (220.51%) | Buy | 10.27 |
| JP Morgan | 06 May 2025 | 13.00 (38.89%) | Buy | 10.27 |
| Cantor Fitzgerald | 29 Apr 2025 | 20.00 (113.68%) | Buy | 8.44 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |